News articles about CVS Health (NYSE:CVS) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CVS Health earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news stories about the pharmacy operator an impact score of 46.1065862073712 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- CVS to offer home dialysis for kidney patients (dispatch.com)
- Consumer Demand for Telehealth, Home Health Services Fueling Revenue Opportunities for Healthcare Companies (virtual-strategy.com)
- CVS Sued for Exposing HIV Status of 6,000 Patients in Mailing (towleroad.com)
- CVS Health delves deeper into monitoring, providing care for chronic diseases (chainstoreage.com)
- CVS accused of releasing patients’ HIV status (washingtonblade.com)
CVS has been the subject of several recent research reports. Raymond James Financial raised CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 price target for the company in a report on Thursday, January 4th. They noted that the move was a valuation call. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target for the company in a report on Friday, January 5th. Mizuho set a $95.00 price target on CVS Health and gave the stock a “buy” rating in a report on Wednesday, January 24th. Needham & Company LLC raised their target price on CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Finally, Vetr downgraded CVS Health from a “buy” rating to a “hold” rating and set a $77.11 target price for the company. in a report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $86.81.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, beating the consensus estimate of $1.88 by $0.04. The company had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.71 EPS. sell-side analysts forecast that CVS Health will post 6.37 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Friday, April 20th. CVS Health’s dividend payout ratio is currently 33.90%.
In related news, EVP Helena Foulkes sold 19,965 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the transaction, the executive vice president now directly owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.61% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cvs-health-cvs-stock-price/2025553.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.